Avdagic Selma Sijercic, Brkic Harun, Avdagic Harun, Smajic Jasmina, Hodzic Samir
Clinic for Anesthesiology and Reanimatology, University Clinical Center Tuzla, Tuzla, Bosna i Hercegovina.
Clinic for Neurosurgery, University Clinical Center Tuzla, Tuzla, Bosna i Hercegovina.
Med Arch. 2015 Oct;69(5):280-3. doi: 10.5455/medarh.2015.69.280-283. Epub 2015 Oct 4.
One of the complications aneurysms subarachnoid hemorrhage is the development of vasospasm, which is the leading cause of disability and death from ruptured cerebral aneurysm.
To evaluate the significance of previous comorbidities on early outcome of patients with subarachnoid hemorrhage caused by rupture of a cerebral aneurysm in the prevention of vasospasm.
The study had prospective character in which included 50 patients, whose diagnosed with SAH caused by the rupture of a brain aneurysm in the period from 2011to 2013. Two groups of patients were formed. Group I: patients in addition to the standard initial treatment and "3H therapy" administered nimodipine at a dose of 15-30 mg / kg bw / h (3-10 ml) for the duration of the initial treatment. Group II: patients in addition to the standard initial treatment and "3H therapy" administered with MgSO4 at a dose of 12 grams in 500 ml of 0.9% NaCl / 24 h during the initial treatment.
Two-thirds of the patients (68%) from both groups had a good outcome measured with values according to GOS scales, GOS IV and V. The poorer outcome, GOS III had 20% patients, the GOS II was at 2% and GOS I within 10% of patients. If we analyze the impact of comorbidity on the outcome, it shows that there is a significant relationship between the presence of comorbidity and outcomes. The patients without comorbidity (83.30%) had a good outcome (GOS IV and V), the same outcome was observed (59.4%) with comorbidities, which has a statistically significant difference (p = 0.04). Patients without diabetes (32%) had a good outcome (GOS IV and V), while the percentage of patients with diabetes less frequent (2%) with a good outcome, a statistically significant difference (p = 0.009).
The outcome of treatment 30 days after the subarachnoid hemorrhage analyzed values WFNS and GOS, is not dependent on the method of prevention and treatment of vasospasm. Most concomitant diseases in patients with SAH which, requiring additional treatment measures are arterial hypertension and diabetes mellitus. The best predictors in the initial treatment of patients with subarachnoid hemorrhage caused by rupture of a cerebral aneurysm has the presence of comorbidity, which has statistical significance.
蛛网膜下腔出血的并发症之一是血管痉挛的发生,这是破裂性脑动脉瘤导致残疾和死亡的主要原因。
评估既往合并症对脑动脉瘤破裂所致蛛网膜下腔出血患者预防血管痉挛早期预后的意义。
本研究具有前瞻性,纳入了2011年至2013年期间诊断为脑动脉瘤破裂所致蛛网膜下腔出血的50例患者。将患者分为两组。第一组:除标准初始治疗和“3H疗法”外,患者在初始治疗期间以15 - 30mg/kg体重/小时(3 - 10ml)的剂量给予尼莫地平。第二组:除标准初始治疗和“3H疗法”外,患者在初始治疗期间以12克硫酸镁加入500ml 0.9%氯化钠中/24小时的剂量给予硫酸镁。
两组中三分之二的患者(68%)根据GOS量表(GOS IV和V)评估结果良好。预后较差的GOS III级患者占20%,GOS II级为2%,GOS I级在患者中占比不到10%。如果分析合并症对预后的影响,结果显示合并症的存在与预后之间存在显著关系。无合并症的患者(83.30%)预后良好(GOS IV和V),有合并症的患者该比例为59.4%,差异具有统计学意义(p = 0.04)。无糖尿病的患者(32%)预后良好(GOS IV和V),而糖尿病患者预后良好的比例较低(2%),差异具有统计学意义(p = 0.009)。
根据WFNS和GOS分析蛛网膜下腔出血30天后的治疗结果,其并不依赖于血管痉挛的预防和治疗方法。蛛网膜下腔出血患者中大多数需要额外治疗措施的合并症是动脉高血压和糖尿病。脑动脉瘤破裂所致蛛网膜下腔出血患者初始治疗中合并症的存在是最佳预测指标,具有统计学意义。